**Review article:**

**Biosimilars : Simnilarities and Differences**

**Dr Sachin Nandkishor Solanke**

Name of the Institute/college: Dept of Medicine , Govt. Medical College and Hospital, Aurangabad, India

Corresponding author: Dr Sachin Nandkishor Solanke

Date of submission: 05 June 2014; Date of Publication: 22 September 2014

**Abstract:**

In the 1980s novel biological medicines produced by recombinant DNA technology appeared on the horizon. The biopharmaceutical industry has expanded dramatically over the last 30 years since the first successes of recombinant DNA technology. Biopharmaceutical drugs have become an essential part of modern pharmacotherapy. Biopharmaceuticals are well established in biomedicine and have opened new therapy options particularly in disease areas where previously no, or only insufficient, therapies were available. These comprise proteins derived from recombinant DNA technology and hybridoma technique. Examples include biological proteins (cytokines, hormones, and clotting factors), monoclonal antibodies, vaccines, cell and tissue based therapies. The rising pressure of cost-containment in all major markets is driving the uptake of generics and also creates a demand for biosimilars. However, the cost and duration of development for biosimilars are much greater than for small-molecule generics, and presents a significant barrier to entry and a resistor of biosimilars market growth.

Keywords : Biopharmaceuticals , DNA Technology